HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Bottom-Up

Shanghai Junshi Biosciences  / Equity Bottom-Up

<ul>
<li>We analyzed <a href="https://www.smartkarma.com/entities/shanghai-junshi-bioscience-h" target="_blank" data-smartkarma-citation="entities:27760:1" rel="noopener">Shanghai Junshi Bioscience Co. Ltd. (1877 HK)</a>’s pipeline, the commercialization strategy, the talents, the outlook and the related concerns.</li>
<li>We also analyzed what the valuation system ecology of top and first-class companies could be like as well as the logic behind.</li>
<li>Revolutionary companies can establish new business models, change the game rule at any time and have the initiative in hands. So, will Junshi progress or go backwards instead?</li>
</ul>


We analyzed Shanghai Junshi Bioscience Co. Ltd. (1877 HK)’s pipeline, the commercialization strategy, the talents, the outlook and the related concerns.
We also analyzed what the valuation system ecology of top and first-class companies could be like as well as the logic behind.
Revolutionary companies can establish new business models, change the game rule at any time and have the initiative in hands. So, will Junshi progress or go backwards instead?


Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?

Pan-Asia Index Rebalances/ Events/ Delta One, Periscope Analytics

Brian Freitas

Pan-Asia Index Rebalances/ Events/ Delta One

Event-Driven

Orient Overseas International / Event-Driven

<ul>
<li>The review period for the March review of the HSCI ends on 31 December. There are expected to be a lot more inclusions than deletions at the review.</li>
<li>There are quite a few stocks that should be included following their listing over the last couple of months while others are now potential inclusions after passing the velocity test.</li>
<li>Quite a few of the potential deletions from the HSCI and Stock Connect have large holdings via Southbound Stock Connect and these stock could see some selling.</li>
</ul>


The review period for the March review of the HSCI ends on 31 December. There are expected to be a lot more inclusions than deletions at the review.
There are quite a few stocks that should be included following their listing over the last couple of months while others are now potential inclusions after passing the velocity test.
Quite a few of the potential deletions from the HSCI and Stock Connect have large holdings via Southbound Stock Connect and these stock could see some selling.


HSCI Index Rebalance and Stock Connect: More Inclusions than Exclusions in March

Global Healthcare Analyst

Tina Banerjee

CSPC Pharmaceutical Group / Equity Bottom-Up

<ul>
<li>With its flagship drug being under substantial price cut, CSPC Pharma is focusing on differentiated and innovative product pipeline and collaboration with leading biotech companies to boost future growth.</li>
<li>CSPC Pharma plans to launch over 30 innovative and over 60 generic drugs during 2021–2025. New products are expected to contribute RMB 1 billion revenue in 2022.</li>
<li>Through November, CSPC announced four business development deals for in-licensing four products targeting multiple therapeutic areas for a combined upfront payment of over RMB 300 million.  </li>
</ul>


With its flagship drug being under substantial price cut, CSPC Pharma is focusing on differentiated and innovative product pipeline and collaboration with leading biotech companies to boost future growth.
CSPC Pharma plans to launch over 30 innovative and over 60 generic drugs during 2021–2025. New products are expected to contribute RMB 1 billion revenue in 2022.
Through November, CSPC announced four business development deals for in-licensing four products targeting multiple therapeutic areas for a combined upfront payment of over RMB 300 million.  


CSPC Pharmaceutical (1093 HK): Oncology Portfolio and Rich Pipeline To Improve Revenue Visibility

Thematic (Sector/Industry)

<ul>
<li>Last Friday, the 6th national volume-based purchase (VBP) for insulin released results.</li>
<li>The NHSA issued relevant documents and proposed to implement unified access management for medical consumables, which means that more medical consumables would be included in centralized procurement.</li>
<li>The NHC issued a document promoting the standardized development of digital healthcare industry, which would bring varying degrees of influence to medical institutions and enterprises providing online healthcare services.</li>
</ul>


Last Friday, the 6th national volume-based purchase (VBP) for insulin released results.
The NHSA issued relevant documents and proposed to implement unified access management for medical consumables, which means that more medical consumables would be included in centralized procurement.
The NHC issued a document promoting the standardized development of digital healthcare industry, which would bring varying degrees of influence to medical institutions and enterprises providing online healthcare services.


China Healthcare Weekly (Nov.26)-Insulin VBP Results, Key Policy On Consumables & Digital Healthcare

Equity Capital Markets

Beijing Mabworks Biotech / Equity Capital Markets

<p>On July 18, 2021, <a href="https://www.smartkarma.com/entities/beijing-mabworks-biotech-company-limited" target="_blank" data-smartkarma-citation="entities:33816:1" rel="noopener">Beijing Mabworks Biotech (MWB HK) </a>formally submitted its application to the HKEX for listing on the main board. It should be noted that Mabworks's application for listing on the SSE STAR Market was accepted in September last year, but the Company voluntarily withdrew its application in March this year. Mabworks is a clinical-stage biopharmaceutical company in China focusing on the discovery and development of differentiated antibody drugs. This insight mainly analyzed the clinical-stage drug candidates and related concerns of the Company.</p>

On July 18, 2021, Beijing Mabworks Biotech (MWB HK) formally submitted its application to the HKEX for listing on the main board. It should be noted that Mabworks's application for listing on the SSE STAR Market was accepted in September last year, but the Company voluntarily withdrew its application in March this year. Mabworks is a clinical-stage biopharmaceutical company in China focusing on the discovery and development of differentiated antibody drugs. This insight mainly analyzed the clinical-stage drug candidates and related concerns of the Company.

Pre-IPO Beijing Mabworks Biotech - MIL62 Alone Cannot Save the Situation

Hong Kong

Keymed Biosciences Inc. operates a biotechnology company. The Company focus on the in-house discovery and development of innovative biological therapies. Keymed Biosciences provides services in China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Keymed Biosciences (2162 HK)

Shanghai Junshi Bioscience (1877.HK) - Will Junshi Progress or Go Backwards Instead?

The article mainly analyzed Junshi in terms of the pipeline, commercialization strategy, the talents, the outlook, the related concerns, as well as...

Xinyao (Criss) Wang

HSCI Index Rebalance and Stock Connect: More Inclusions than Exclusions in March

We expect there will be a lot more inclusions than exclusions at the March rebalance of the HSCI. The changes to the index will result in changes...

Brian Freitas

CSPC Pharmaceutical (1093 HK): Oncology Portfolio and Rich Pipeline To Improve Revenue Visibility

Over the next five years, the company is expected to have 35 innovative and 60 generic drugs on the market, which will provide steady revenue stream

Tina Banerjee

China Healthcare Weekly (Nov.26)-Insulin VBP Results, Key Policy On Consumables & Digital Healthcare

This article analyzed the 6th VBP results on insulin, the new and key policies about unified access management on medical consumables and the...

Xinyao (Criss) Wang

Pre-IPO Beijing Mabworks Biotech - MIL62 Alone Cannot Save the Situation

This article mainly analyzed Mabworks Biotech in terms of the important clinical-stage drug candidates (MIL62, MIL93, MBS301, MIL97, MIL95, MIL86,...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)